MACK Merrimack Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MACK

Price (delayed)

$14.685

Market cap

$213.17M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.08

Enterprise value

$207.18M

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive up to $450.0 million in contingent milestone payments related to its sale of ONIVYDE® ...

Highlights
MACK's quick ratio is up by 30% year-on-year and by 12% since the previous quarter
Merrimack Pharmaceuticals's EPS has increased by 27% YoY and by 20% from the previous quarter
MACK's equity is down by 2.6% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.merrimackpharma.com
Peers: GERN CHRS RGEN

Key stats

What are the main financial stats of MACK
Market
Shares outstanding
14.52M
Market cap
$213.17M
Enterprise value
$207.18M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
11.22
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$1.17M
EBITDA
-$1.17M
Free cash flow
-$1.52M
Per share
EPS
-$0.08
Free cash flow per share
-$0.11
Book value per share
$1.31
Revenue per share
$0
TBVPS
$1.34
Balance sheet
Total assets
$19.19M
Total liabilities
$441,000
Debt
$0
Equity
$18.75M
Working capital
$18.74M
Liquidity
Debt to equity
0
Current ratio
43.5
Quick ratio
42.8
Net debt/EBITDA
5.12
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-6.1%
Return on equity
-6.2%
Return on invested capital
-13.7%
Return on capital employed
-6.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MACK stock price

How has the Merrimack Pharmaceuticals stock price performed over time
Intraday
0.03%
1 week
-0.31%
1 month
-0.24%
1 year
16.46%
YTD
9.51%
QTD
-0.58%

Financial performance

How have Merrimack Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$2.04M
Net income
-$1.18M
Gross margin
N/A
Net margin
N/A
MACK's net income is up by 24% year-on-year and by 18% since the previous quarter
The operating income has declined by 18% year-on-year but it has grown by 7% since the previous quarter

Growth

What is Merrimack Pharmaceuticals's growth rate over time

Valuation

What is Merrimack Pharmaceuticals stock price valuation
P/E
N/A
P/B
11.22
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Merrimack Pharmaceuticals's EPS has increased by 27% YoY and by 20% from the previous quarter
The price to book (P/B) is 112% higher than the 5-year quarterly average of 5.3 and 18% higher than the last 4 quarters average of 9.5
MACK's equity is down by 2.6% YoY

Efficiency

How efficient is Merrimack Pharmaceuticals business performance
Merrimack Pharmaceuticals's return on invested capital has increased by 49% QoQ
MACK's ROE is up by 40% YoY and by 17% from the previous quarter
The company's return on assets rose by 38% YoY and by 16% QoQ

Dividends

What is MACK's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Merrimack Pharmaceuticals financials performed over time
MACK's quick ratio is up by 30% year-on-year and by 12% since the previous quarter
The company's current ratio rose by 29% YoY and by 11% QoQ
The debt is 100% less than the equity
MACK's equity is down by 2.6% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.